In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

As a novel small molecule oral PCSK9 inhibitor that can be taken without fasting restrictions, AZD0780 has the potential to be a game changer that could offer LDL-C lowering with greater ...

Thus, combining PCSK9 inhibitors with anti-PD-1/PD-L1 immunotherapy may be a new strategy to improve antitumor effects. Proprotein convertases (PCs) are a unique class of serine proteinases.

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...